IHE:NYE-iShares U.S. Pharmaceuticals ETF (USD)

ETF | Health |

Last Closing

USD 66.93

Change

0.00 (0.00)%

Market Cap

N/A

Volume

0.06M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-17 )

ETFs Containing IHE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 8.30% 81% B- 55% F
Dividend Return 1.50% 100% F 28% F
Total Return 9.80% 86% B+ 49% F
Trailing 12 Months  
Capital Gain 15.78% 52% F 57% F
Dividend Return 1.84% 94% A 26% F
Total Return 17.61% 62% D 52% F
Trailing 5 Years  
Capital Gain 37.02% 71% C- 65% D
Dividend Return 10.04% 94% A 29% F
Total Return 47.06% 76% C+ 62% D
Average Annual (5 Year Horizon)  
Capital Gain 4.38% 48% F 50% F
Dividend Return 5.73% 48% F 47% F
Total Return 1.35% 100% F 33% F
Risk Return Profile  
Volatility (Standard Deviation) 15.38% 71% C- 66% D+
Risk Adjusted Return 37.23% 67% D+ 54% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.